Search research articles
Contact Us
Filters
Showing results (251-260 of 512) with videos related to
Page
of 52
Sort By:
Journal of Telemedicine and Telecare
|
February 8, 2024
Evaluation of the satisfaction and experiences of oncology patients and doctors using teleconsultation during the COVID-19 pandemic
Myrto Kastrisiou, Maryam Karimi, Evangelos Aa Christou, et al.
Frontiers in Oncology
|
April 14, 2022
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer
Brendan Knapp, Laura Mezquita, Siddhartha Devarakonda, et al.
NPJ Precision Oncology
|
July 17, 2021
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Marianne Oulhen, Patrycja Pawlikowska, Tala Tayoun, et al.
Cancer Biomarkers : Section a of Disease Markers
|
November 2, 2016
MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer
Julien Adam, Tony Sourisseau, Ken A Olaussen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2009
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
Carlos Gomez-Roca, Christophe M Raynaud, Frederique Penault-Llorca, et al.
Cardiovascular and Interventional Radiology
|
May 8, 2019
Focus on Recommendations for the Management of Non-small Cell Lung Cancer
Pernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
Cancer Treatment Reviews
|
August 23, 2022
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
Maria Kfoury, Marie Najean, Ariane Lappara, et al.
Cancer Research
|
May 3, 2017
Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer Patients
Emma Pailler, Marianne Oulhen, Isabelle Borget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2026
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX
Marco Tagliamento, Marco Bruzzone, Eva Blondeaux, et al.
Page
of 52
Search research articles
Search
Showing results (251-260 of 512) with videos related to
Sort By:
Page
of 52
Journal of Telemedicine and Telecare
|
February 8, 2024
Evaluation of the satisfaction and experiences of oncology patients and doctors using teleconsultation during the COVID-19 pandemic
Myrto Kastrisiou, Maryam Karimi, Evangelos Aa Christou, et al.
Frontiers in Oncology
|
April 14, 2022
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer
Brendan Knapp, Laura Mezquita, Siddhartha Devarakonda, et al.
NPJ Precision Oncology
|
July 17, 2021
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Marianne Oulhen, Patrycja Pawlikowska, Tala Tayoun, et al.
Cancer Biomarkers : Section a of Disease Markers
|
November 2, 2016
MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer
Julien Adam, Tony Sourisseau, Ken A Olaussen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2009
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
Carlos Gomez-Roca, Christophe M Raynaud, Frederique Penault-Llorca, et al.
Cardiovascular and Interventional Radiology
|
May 8, 2019
Focus on Recommendations for the Management of Non-small Cell Lung Cancer
Pernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
Cancer Treatment Reviews
|
August 23, 2022
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
Maria Kfoury, Marie Najean, Ariane Lappara, et al.
Cancer Research
|
May 3, 2017
Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer Patients
Emma Pailler, Marianne Oulhen, Isabelle Borget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2026
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX
Marco Tagliamento, Marco Bruzzone, Eva Blondeaux, et al.
Page
of 52